Approval

FDA grants accelerated approval to subcutaneous amivantamab in head and neck cancer

Johnson & Johnson's Rybrevant Faspro won US accelerated approval as a single agent for head and neck squamous cancer that has recurred or spread after platinum chemotherapy and a PD-(L)1 antibody, excluding HPV-linked oropharyngeal tumours. In the OrigAMI-4 cohort of 102 patients, 42% responded. Serious adverse reactions hit 39%, and full approval may hinge on the OrigAMI-5 trial.

Written by Gosset from public sources. Source types: Press release · News article. Sources are available to Gosset users. Log in to see them.

Schematic animation of EGFR and MET receptors on a tumour cell surface, a Y-shaped bispecific antibody binding both from outside, ligands kept off the receptors, and immune cells engaging the antibody's stem.
Amivantamab: one antibody for EGFR and MET. Watch the mechanism animation on the amivantamab page.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call